RecruitingPhase 1NCT05800873

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

Sponsor

Everest Medicines (China) Co.,Ltd.

Enrollment

30 participants

Start Date

May 15, 2023

Study Type

INTERVENTIONAL

Conditions

Primary Membranous Nephropathy

Summary

EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EVER001 and a drug called EVER001 for people with primary membranous nephropathy. The study is currently recruiting participants at 19 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEVER001

A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.

DRUGEVER001

A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.

Locations(19)

The Second Xiangya Hospital Of Central South University

Changsha, Changsha, China

The First Affiliated Hospital of PLA Army Medical University

Chongqing, Chongqing Municipality, China

The Third Affiliated Hospital,Sun Yat Sen University

Guangzhou, Guangdong, China

Peking University Shenzhen Hospital

Shenzhen, Guangdong, China

The Second Affiliated Hospital of Harbin Medical University

Harbin, Harbin, China

Xiangya Third Hospital, Central South University

Changsha, Hunan, China

The First Affiliated Hospital of Baotou Medical College

Baotou, Inner Mongolia, China

Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

The First Affiliated Hospital of Medical college of Xi'an Jiaotong University

Xian, Shanxi, China

Sichuan Province People's Hospital

Chengdu, Sichuan, China

Second Hospital of Shanxi Medical University

Shanxi, Taiyuan, China

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

The first affliated hospital of NingBo university

Ningbo, Zhejiang, China

Taizhou Hospital of Zhejiang Province

Taizhou, Zhejiang, China

Peking University First Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05800873

Related Trials

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT0709684343 locations

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT0757174622 locations

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275102 locations

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT0569661331 locations

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT0715778740 locations